Treatment Advances Bring New Hope in Gastric Cancer

Bonnie Gillis
Published: Tuesday, Jan 07, 2014
Dr Charles S. Fuchs

Charles S. Fuchs, MD, MPH

Several new drugs have recently shown promise for the treatment of gastric cancer, including rilotumumab, ramucirumab, and anti-HER2 agents, according to a presentation at the 2013 Chemotherapy Foundation Symposium.

Promising Agents in Advanced Gastric Cancer

Agent Target Trial OS advantage versus control (months)
Trastuzumab HER2 ToGAa 2.7
Ramucirumab VEGFR-2 REGARDb 1.4
Rilotumumab c-MET Phase II studyc 5.4

aPatients were randomized to capecitabine or 5-FU (physician’s choice) plus cisplatin or the same chemotherapy plus trastuzumab.

bPatients were randomized to ramucirumab versus placebo.

cOS benefit was observed in subset of patients with high MET expression who received rilotumumab plus ECX versus ECX alone.
... to read the full story

To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication